Literature DB >> 8505775

A national survey of the prevalence of chloroquine resistant Plasmodium falciparum in Burkina Faso.

L Del Nero1, L Lamizana, V Pietra, G Rotigliano.   

Abstract

Plasmodium falciparum susceptibility to chloroquine was investigated in 10 areas of Burkina Faso in the rainy seasons in 1990-1991. The 7-days in-vivo test was carried out from August to November on children aged 2-8 years with monospecific P. falciparum infection (asexual parasitaemia > 800 microliters-1 of blood), axillary temperature < 37.5 degrees C, and a negative Bergqvist urine test for 4-aminoquinolines. Among 2190 children screened, 366 were selected. Blood samples were collected on days 0, 2, 4 and 7 by finger-prick, and 100 microscopic fields of thick and thin smears were examined for parasite density and species identification. Chloroquine was given under supervision at the standard dose of 25 mg kg-1 over three days (days 0, 1 and 2) with an observation period of one hour after treatment. Parasitaemia did not clear in 63 cases (17.2%) with a 13.4% RII response and 3.8% RIII response. The results do not seem to indicate a decline in the sensitivity of P. falciparum to chloroquine in Burkina Faso during the past two years.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505775

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  2 in total

1.  Antiplasmodial activity of alkaloid extracts from Pavetta crassipes (K. Schum) and Acanthospermum hispidum (DC), two plants used in traditional medicine in Burkina Faso.

Authors:  S Sanon; N Azas; M Gasquet; E Ollivier; V Mahiou; N Barro; N Cuzin-Ouattara; A S Traore; F Esposito; G Balansard; P Timon-David
Journal:  Parasitol Res       Date:  2003-04-04       Impact factor: 2.289

2.  Rapid urban malaria appraisal (RUMA) I: epidemiology of urban malaria in Ouagadougou.

Authors:  Shr-Jie Wang; Christian Lengeler; Thomas A Smith; Penelope Vounatsou; Diallo A Diadie; Xavier Pritroipa; Natalie Convelbo; Mathieu Kientga; Marcel Tanner
Journal:  Malar J       Date:  2005-09-16       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.